Concerning the structure of apoE

Protein Science

Volumn 22, Issue 12, 2013, Pages 1820-1825

  Frieden, Carl ^a   Garai, Kanchan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; ApoE isoforms; Domain interactions; Salt bridges; Structural changes

Indexed keywords

AMINO ACID; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; ISOPROTEIN; LIPID;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL METABOLISM; ENZYME ASSAY; ENZYME STRUCTURE; GENE MUTATION; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER'S DISEASE; APOE ISOFORMS; DOMAIN INTERACTIONS; SALT BRIDGES; STRUCTURAL CHANGES;

ALZHEIMER DISEASE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84892909138     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2379     Document Type: Article

References (41)

1. Shore VG, Shore B (1973) Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 12:502-507.
2. Utermann G, Hees M, Steinmetz A (1977) Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269:604-607.
3. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, Goldstein JL, Brown MS, Schonfeld G, Hazzard WR, Blum C (1982) Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 23:911-914.
4. Weisgraber KH, Rall SC Jr, Mahley RW (1981) Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 256:9077-9083.
5. Rall SC Jr, Weisgraber KH, Mahley RW (1982) Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 257:4171-4178.
6. Weisgraber KH, Innerarity TL, Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:2518-2521.
7. Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 263:6240-6248.
8. Perugini MA, Schuck P, Howlett GJ (2000) Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid. J Biol Chem 275: 36758-36765.
9. Garai K, Frieden C (2010) The association-dissociation behavior of the ApoE proteins: Kinetic and equilibrium studies. Biochemistry 49:9533-9541.
10. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxylterminal domains. J Biol Chem 263:6249-6258.
11. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252:1817-1822.
12. Sivashanmugam A, Wang J (2009) A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoproteinbinding and for receptor-binding activity. J Biol Chem 284:14657-14666.
13. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH (1996) Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 3:718-722.
14. Dong J, Peters-Libeu CA, Weisgraber KH, Segelke BW, Rupp B, Capila I, Hernaiz MJ, LeBrun LA, Linhardt RJ (2001) Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry 40:2826-2834.
15. Chou PY, Fasman GD (1974) Prediction of protein conformation. Biochemistry 13:222-245.
16. Mahley RW (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240:622-630.
17. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
18. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA (1994) Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 269:22358-22365.
19. Dong LM, Weisgraber KH (1996) Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271:19053-19057.
20. Hatters DM, Peters-Libeu CA, Weisgraber KH (2005) Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4. J Biol Chem 280:26477-26482.
21. Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E structure: Insights into function. Trends Biochem Sci 31:445-454.
22. Fan D, Li Q, Korando L, Jerome WG, Wang J (2004) A monomeric human apolipoprotein E carboxyl-terminal domain. Biochemistry 43:5055-5064.
23. Zhang Y, Vasudevan S, Sojitrawala R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG, Weisgraber K, Li Q, Wang J (2007) A monomeric, biologically active, full-length human apolipoprotein E. Biochemistry 46:10722-10732.
24. Chen J, Li Q, Wang J (2011) Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA 108:14813-14818.
25. Frieden C, Garai K (2012) Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci USA 109:8913-8918.
26. Huang RYC, Garai K, Frieden C, Gross ML (2011) Hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry determine the interface and dynamics of apolipoprotein E oligomerization. Biochemistry 50:9273-9282.
27. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM (2013) ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA 110:E1807-E1816.
28. Strittmatter WJ, Saunders AM, Schmechel D, Pericak- Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981.
29. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B (1993) Apolipoprotein E: Binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 192:359-365.
30. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert J-M, Raussens V (2011) High ability of apolipoprotein E4 to stabilize amyloid-b peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J 25:1585-1595.
31. Basak JM, Kim J, Pyatkivskyy Y, Wildsmith KR, Jiang H, Parsadanian M, Patterson BW, Bateman RJ, Holtzman DM (2012) Measurement of apolipoprotein E and amyloid beta clearance rates in the mouse brain using bolus stable isotope labeling. Mol Neurodegen 7: 14.
32. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloidbeta peptide clearance. Sci Transl Med 3:89ra57.
33. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE (2013) Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimers Res Ther 5:33.
34. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein e and apolipoprotein e receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006312.
35. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, LaDu MJ (2012) APOE4-specific changes in Ab accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 287:41774-41786.
36. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ (2013) Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 288:5914-5926.
37. Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji ZS, Balestra ME, Walker DW, Xu Q, Jeong DE, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW (2012) Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem 287:5253-5266.
38. Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Stewart FR, Basak JM, Holtzman DM (2012) AntiapoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med 209:2149-2156.
39. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103:5644-5651.
40. Mahley RW, Huang Y (2009) Alzheimer disease: Multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Ann Neurol 65:623-625.
41. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y (2005) Lipid- and receptorbinding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA 102:18694-18699.